NASDAQ:MDSO Medidata Solutions (MDSO) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free MDSO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$92.21▼$92.2650-Day Range$91.79▼$92.2552-Week Range$60.10▼$98.60Volume7.30 million shsAverage Volume1.24 million shsMarket Capitalization$5.76 billionP/E Ratio96.06Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Medidata Solutions alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Medidata Solutions Stock (NASDAQ:MDSO)Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management. It also provides professional services, such as implementation, sponsor enablement, strategic consulting, partner support, and e-learning and training. The company markets and sells its cloud-based solutions through a direct sales force and through relationships with channel and strategic partners. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; academic research centers, government, and other non-profit organizations; and other non-profit organizations; and contract research organizations and other entities engaged in clinical trials. The company was founded in 1999 and is headquartered in New York, New York.Read More Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. MDSO Stock News HeadlinesNovember 20, 2023 | tmcnet.comFortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical TrialsNovember 13, 2023 | finance.yahoo.comGeorge Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical TrialsApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."November 8, 2023 | msn.comMedidata and EDETEK partner for clinical data managementNovember 8, 2023 | businesswire.comMedidata Announces New Data Integration Solutions to Accelerate Clinical Trials: Clinical Data Studio and Health Record ConnectNovember 7, 2023 | tmcnet.comMedidata and EDETEK Announce Partnership to Revolutionize Global Clinical Trial Data ManagementNovember 6, 2023 | finance.yahoo.comTFS HealthScience Becomes First CRO to Adopt Medidata Detect, Improving Data Sharing Efficiency and Product DevelopmentNovember 2, 2023 | finance.yahoo.comMedidata NEXT New York to Unveil New Vision for Life Sciences InnovationApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."October 27, 2023 | msn.comMedidata and Catalyst expand oncology trial collaborationOctober 26, 2023 | tmcnet.comMedidata Announces Expansion of Multi-Year Partnership with Catalyst Clinical Research for Oncology TrialsSeptember 21, 2023 | msn.comMedidata unveils new solution to boost clinical trial diversityApril 13, 2023 | finance.yahoo.comPROMETRIKA Achieves Accreditation in Medidata Rave RTSMApril 12, 2023 | finance.yahoo.comLaunch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial DevelopmentApril 3, 2023 | thestreet.comAdvent Soars, Integrated Leaps: Tech Winners & LosersMarch 30, 2023 | finance.yahoo.comCustomer Award Winners Unveiled at Medidata NEXT ConferenceMarch 23, 2023 | finance.yahoo.comGlobal Medidata Certification Model Helps Rave EDC Study Builders Create New Value for Their CompaniesFebruary 6, 2023 | businesswire.comIDC MarketScape Names Medidata a Leader in Life Science R&D Risk-Based Monitoring Solutions Vendor AssessmentFebruary 3, 2023 | benzinga.comMedidata Experts Present New Insights on Risk-Based Quality Management, Decentralized Clinical Trials, and Real World Data at SCOPE SummitDecember 13, 2022 | finance.yahoo.comEverest Group Names Medidata a ‘Leader’ and ‘Star Performer’ in Decentralized Clinical Trial PlatformsDecember 8, 2022 | yahoo.comMedidata Receives Prestigious Innovation Award from Reagan-Udall Foundation for the FDADecember 6, 2022 | nz.finance.yahoo.comMedidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient ExperienceNovember 22, 2022 | tmcnet.comMedidata Patient Insights Leader Alicia Staley Honored by National Coalition for Cancer SurvivorshipNovember 15, 2022 | technews.tmcnet.comMedidata Launches Rave Companion, the First Scalable Solution for Automating EHR Data Entry into Rave EDCOctober 27, 2022 | finance.yahoo.comBoehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical TrialsOctober 27, 2022 | finance.yahoo.comeClinical Solutions Achieves New Medidata Accreditation Enhancing Digital Services to Support High Quality, Faster Digital Trials at ScaleOctober 13, 2022 | finance.yahoo.comNew Medidata Technology Helps Sponsors and CROs Improve Diversity and Inclusion in Clinical TrialsSee More Headlines Receive MDSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medidata Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Prepackaged Software Sub-IndustryHealth Care Technology Current SymbolNASDAQ:MDSO CUSIP58471A10 CIK1453814 Webwww.mdsol.com Phone212-918-1800FaxN/AEmployees1,998Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.96 Trailing P/E Ratio96.06 Forward P/E Ratio118.23 P/E Growth6.95Net Income$51.92 million Net Margins6.43% Pretax MarginN/A Return on Equity8.64% Return on Assets5.73% Debt Debt-to-Equity Ratio0.27 Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual Sales$635.70 million Price / Sales9.06 Cash Flow$1.69 per share Price / Cash Flow54.55 Book Value$10.32 per share Price / Book8.94Miscellaneous Outstanding Shares62,460,000Free FloatN/AMarket Cap$5.76 billion OptionableOptionable Beta1.22 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Tarek A. Sherif (Age 57)Co-Founder, Chairman & CEO Mr. Glen M. de Vries (Age 47)Co-Founder, Pres & Director Mr. Rouven Bergmann (Age 46)Chief Financial Officer Mr. Michael Pray (Age 53)Exec. VP - Gen. Mang. of Global Sales Ms. Jill Larsen (Age 46)Exec. VP - HR & Chief HR Officer Key CompetitorsCertaraNASDAQ:CERTBlueprint MedicinesNASDAQ:BPMCApellis PharmaceuticalsNASDAQ:APLSRevolution MedicinesNASDAQ:RVMDIonis PharmaceuticalsNASDAQ:IONSView All Competitors MDSO Stock Analysis - Frequently Asked Questions How were Medidata Solutions' earnings last quarter? Medidata Solutions Inc (NASDAQ:MDSO) issued its quarterly earnings data on Monday, July, 22nd. The company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.31. The company earned $180.50 million during the quarter, compared to analysts' expectations of $179.95 million. Medidata Solutions had a trailing twelve-month return on equity of 8.64% and a net margin of 6.43%. The firm's revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. What other stocks do shareholders of Medidata Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medidata Solutions investors own include NVIDIA (NVDA), Applied Materials (AMAT), Salesforce (CRM), Gilead Sciences (GILD), Allergan (AGN), Alibaba Group (BABA), Just Eat Takeaway.com (GRUB), International Business Machines (IBM), Western Digital (WDC) and BioMarin Pharmaceutical (BMRN). This page (NASDAQ:MDSO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medidata Solutions Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
